Meeting
2011 ASCO Annual Meeting
Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer.
Authors
T. M. A. Abdel-Fatah
Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom
T. M. A. Abdel-Fatah , P. D. Dickinson , P. Moseley , J. S. Reis-Filho , A. R. Green , I. O. Ellis , S. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 1024)
Abstract #
1024
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2012 Breast Cancer Symposium
Single-institution experience with neoadjuvant chemotherapy for metaplastic breast cancer (MBC).
First Author: Anna Kaminsky
Poster
2016 ASCO Annual Meeting
Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.
First Author: Priyanka Sharma
Poster
2013 Breast Cancer Symposium
BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy.
First Author: Rupert Bartsch
Poster
2013 ASCO Annual Meeting
Prognostic significance of reduction rate of Ki-67 after neoadjuvant chemotherapy in breast cancer patients with non-pCR.
First Author: Nobuaki Matsubara